Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US-2019367561-A1 · Dec 5, 2019 · US
Recombinant virus with diminished latency and methods of using same
US11305009B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11305009-B2 |
| Application number | US-201816195247-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 19, 2018 |
| Priority date | Nov 9, 2006 |
| Publication date | Apr 19, 2022 |
| Grant date | Apr 19, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of inhibiting latent viral infection, comprising administering to a subject a recombinant virus comprising all or a portion of a herpes virus genome, wherein the genome has a promoter for a latency gene or transcript altered or modified, and the gene or transcript is expressed from the virus genome during virus replication. 2. The method of claim 1 , wherein the viral infection is from a virus selected from the group consisting of herpes simplex virus, varicella-zoster virus, Marek's disease virus, pseudorabies virus and cytomegalovirus. 3. The method of claim 1 , wherein the promoter for the latency gene or transcript is replaced by a heterologous promoter. 4. The method of claim 1 , wherein the genome comprises a deletion in the latency gene or transcript at its native location, and the latency gene or transcript is located at a different location in the viral genome and is expressed from a heterologous promoter. 5. The method of claim 1 , wherein the latency gene is a VZV gene selected from the group consisting of ORF4, ORF21, ORF29, ORF62, ORF63 and ORF66. 6. The method of claim 1 , wherein the latency gene or transcript is at a different location in the genome relative to its native location and comprises at least one mutation. 7. The method of claim 6 , wherein the latency gene is VZV ORF29 and the mutation is a deletion or substitution in the nuclear localization sequence that impairs the ability of ORF29 to translocate to the nucleus.
Assignees
Inventors
Classifications
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
Viral antigens · CPC title
- A61K39/25Primary
Varicella-zoster virus · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
Methods of inactivation or attenuation · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11305009B2 cover?
- The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.
- Who is the assignee on this patent?
- Us Health
- What technology area does this patent fall under?
- Primary CPC classification A61K39/25. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).